Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial

Anti-Cancer Drugs

Volumn 21, Issue 1, 2010, Pages 101-106

  Perdonà, Sisto ^a   Di Lorenzo, Giuseppe ^b   Cantiello, Francesco ^f   Damiano, Rocco ^f   De Sio, Marco ^c   Masala, Daniele ^d   Bruni, Gianni ^e   Gallo, Luigi ^a   Federico, Piera ^b   Quattrone, Carmelo ^c   Pizzuti, Mariano ^c   Autorino, Riccardo ^c  

^a UOC Urologia   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Ospedale Cardarelli   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Bacillus Calmette Gu rin; Failure; Gemcitabine; Nonmuscle invasive bladder cancer

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BCG VACCINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; GEMCITABINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RESISTANCE; CARCINOMA IN SITU; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; DRUG CHOICE; DYSURIA; FEMALE; FEVER; HEMATURIA; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE RISK; SUPERFICIAL CANCER; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, INTRAVESICAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BCG VACCINE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 74349097142     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283324d83     Document Type: Article

References (31)

1. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus calmetteguerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964-1970.
2. Bohle A, Bock PR. Intravesical bacille calmette-guerin versus mitomycin c in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology 2004; 63:682-686.
3. Bohle A, Jocham D, Bock PR. Intravesical bacillus calmette-guerin versus mitomycin c for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169:90-95.
4. Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 2006; 49:790-797.
5. Sylvester RJ, van der Meijden APM,Witjes JA, Kurth KH. Bacillus Calmette- Guerin versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005; 174:86-91.
6. Huguet J, Crego M, Sabate S, Salvador J, Palou J, Villavicencio H. Cystectomy in patients with high risk superficial bladder tumours who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005; 48:53-59.
7. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumours. J Urol 2003; 169:1706-1708.
8. Babjuk M, OosterlinckW, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54:303-314.
9. Joudi FN, O'Donnell MA. Second-line intravesical therapy versus cystectomy for bacille Calmette-Guerin (BCG) failures. Curr Opin Urol 2004; 14:271-275.
10. Perdonà S, Autorino R, Damiano R, De Sio M, Morrica B, Gallo L, et al. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer 2008; 112:75-83.
11. El KF, Flechon A. Gemcitabine in bladder cancer. Expert Opin Pharmacother 2007; 8:3251-3256.
12. Gontero P, Marini L, Frea B. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. BJU Int 2005; 96:970-976.
13. Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, et al. Phase I trial of intravesical gemcitabine in bacillus calmette-guerin-refractory transitional-cell carcinoma of the bladder. J ClinOncol 2002; 20:3193-3198.
14. Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P, et al. Phase II trial of intravesical gemcitabine in bacille calmette-gué rinrefractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24:2729-2734.
15. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466-475.
16. Nieder AM, Brausi M, Lamm D, O'Donnell M, Tomita K, Woo H, et al. Management of stage T1 tumours of the bladder: international consensus panel. Urology 2005; 66:108-125.
17. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13:176-181.
18. Schrier BPH, Hollander MP, van Rhijn BWG, Ijzer S, Kiemeney LALM, Witjes JA. Prognosis of muscle invasive bladder cancer: difference between primary and progressive tumours: possible implications for therapy. Eur Urol 2004; 45:292-296.
19. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19:666-675.
20. Sarosdy MF, Manyak MJ, Sagalowsky AI, Belldegrun A, Benson MC, BihrleW, et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille calmette-guerin. Urology 1998; 5:226-231.
21. O'Donnell MA, Lilli K, Leopold C. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004; 172:888-893.
22. Van Der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004; 46:65-71.
23. Waidelich R, Stepp H, Baumgartner R,Weninger E, Hofstetter A, Kriegmair M. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 2001; 165:1904-1907.
24. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of bacillus calmette-guerin refractory carcinoma in situ of the bladder. J Urol 2000; 163:761-767. (Pubitemid 30091611)
25. Barlow L, McKiernan J, Sawczuk I, Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Gué rin therapy. BJU Int 2009; 104:1098-1102.
26. Bartoletti R, Cai T, Gacci M, Giubilei G, Viggiani F, Santelli G, et al. TUR (Toscana Urologia) Group. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology 2005; 66:726-731.
27. Gacci M, Bartoletti R, Cai T, Nerozzi S, Pinzi N, Repetti F, et al. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol Int 2006; 76:106-111.
28. Gunelli R, Bercovich E, Nanni O, Ballardini M, Frassineti GL, Giovannini N, et al. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer 2007; 97:1499-1504.
29. Bassi P, De Marco V, Tavolini IM, Longo F, Pinto F, Zucchetti M, et al. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Gué rin therapy. Urol Int 2005; 75:309-313.
30. Gontero P, Frea B. Actual experience and future development of gemcitabine in superficial bladder cancer. Ann Oncol 2006; 17 (Suppl 5): 123-128.
31. Hendricksen K, Witjes JA. Intravesical gemcitabine: an update of clinical results. Curr Opin Urol 2006; 16:361-366.